Initial experience with oral valganciclovir for pre-emptive cytomegalovirus therapy after lung transplantation

Wiener Klinische Wochenschrift

Volumn 117, Issue 13-14, 2005, Pages 480-484

  Aigner, Clemens ^a   Jaksch, Peter ^a   Winkler, Guenther ^a   Czebe, Kriztina ^a   Taghavi, Shahrokh ^a   Marta, Gabriel ^a   Klepetko, Walter ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

CMV; Cytomegalovirus; Lung transplantation; Pre emptive therapy; Valganciclovir

Indexed keywords

GANCICLOVIR; PRODRUG; VALGANCICLOVIR;

ADULT; ARTICLE; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; FEMALE; HUMAN; LEUKOPENIA; LUNG LAVAGE; LUNG TRANSPLANTATION; MALE; POLYMERASE CHAIN REACTION; PROPHYLAXIS;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PILOT PROJECTS; POSTOPERATIVE CARE; TREATMENT OUTCOME;

EID: 23844521655     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-005-0413-0     Document Type: Article

References (17)

1. Gotzinger P, Sautner T, Wamser P, Gebhard P, Barlan M, Steiniger R, Fugger R, Muhlbacher F (1996) Early postoperative infections after liver transplantation-pathogen spectrum and risk factors. Wien Klin Wochenschr 108: 795-801
2. Antretter H, Hofer D, Hangler H, Larcher C, Polzl G, Hormann C, Margreiter J, Margreiter R, Laufer G, Bonatti H (2004) Is it possible to reduce CMV-infections after heart-transplantation with a three-months antiviral prophylaxis? 7 years experience with ganciclovir. Wien Klin Wochenschr 116: 542-551
3. Ciancio G, Burke GW, Mattiazzi A, Leibovici Z, Dowdy L, Roth D, Kupin W, Rosen A, Jorge D, Cirocco RE, Miller J (2004) Cytomegalovirus prophylaxis with valganciclovir in kidney, pancreas-kidney, and pancreas transplantation. Clin Transplant 18: 402-406
4. Fishman JA, Rubin RH (1998) Infection in organ-transplant recipients. N Engl J Med 338: 1741-1751
5. Balthesen M, Messerle M, Reddehase MJ (1993) Lungs are a major organ site of cytomegalovirus latency and recurrence. J Virol 67: 5360-5366
6. Zamora MR (2002) Controversies in lung transplantation: management of cytomegalovirus infections. J Heart Lung Transplant 21: 841-849
7. Westall GP, Michaelides A, Williams TJ, Snell GI, Kotsimbos TC (2003) Bronchiolitis obliterans syndrome and early human cytomegalovirus DNAaemia dynamics after lung transplantation. Transplantation 75: 2064-2068
8. Luckraz H, Sharples L, McNeil K, Wreghitt T, Wallwork J (2003) Cytomegalovirus antibody status of donor/recipient does not influence the incidence of bronchiolitis obliterans syndrome in lung transplantation. J Heart Lung Transplant 22: 287-291
9. Egan JJ, Lomax J, Barber L, Lok SS, Martyszczuk R, Yonan N, Fox A, Deiraniya AK, Turner AJ, Woodcock AA (1998) Pre-emptive treatment for the prevention of cytomegalovirus disease: in lung and heart transplant recipients. Transplantation 65: 747-752
10. Kelly J, Hurley D, Raghu G (2000) Comparison of the efficacy and cost effectiveness of pre-emptive therapy as directed by CMV antigenemia and prophylaxis with ganciclovir in lung transplant recipients. J Heart Lung Transplant 19: 355-359
11. Noble S, Faulds D (1998) Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 56: 115-146
12. Bhorade SM, Lurain NS, Jordan A, Leischner J, Villanueva J, Durazo R, Creech S, Vigneswaran WT, Garrity ER (2002) Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients. J Heart Lung Transplant 21: 1274-1282
13. Hoffman VF, Skiest DJ (2000) Therapeutic developments in cytomegalovirus retinitis. Expert Opin Investig Drugs 9: 207-220
14. Reusser P (2001) Oral valganciclovir: a new option for treatment of cytomegalovirus infection and disease in immunocompromised hosts. Expert Opin Investig Drugs 10: 1745-1753
15. Somerville KT (2003) Cost advantages of oral drug therapy for managing cytomegalovirus disease. Am J Health Syst Pharm 60 [Suppl 8]: S9-12
16. Czock D, Scholle C, Rasche FM, Schaarschmidt D, Keller F (2002) Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. Clin Pharmacol Ther 72: 142-150
17. Boivin G, Goyette N, Gilbert C, Roberts N, Macey K, Paya C, Pescovitz MD, Humar A, Dominguez E, Washbum K, Blumberg E, Alexander B, Freeman R, Heaton N, Covington E (2004) Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis 189: 1615-1618